Pluripotent Cell Induction via Mechanical and Chemical Stress

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for generating pluripotent cells rely on limited tissue sources or the introduction of exogenous reprogramming factors, which are inefficient and controversial, and there is no direct evidence that healthy adult somatic cells can be converted to pluripotent states without specific manipulation.

Innovation Solution

Subjecting somatic differentiated cells to mechanical stimulation and chemical stress, including adenosine triphosphate (ATP) concentrations between 1 mM and 50 mM and a pH of 4.5 to 6.0, to induce pluripotency without the need for exogenous gene introduction or cell fusion, resulting in cells expressing embryonic stem cell markers and having a more pluripotent phenotype.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If exogenous reprogramming factors are introduced to generate pluripotent cells, then pluripotency can be achieved, but the method becomes complex and controversial with potential harmful effects

Engineering Contradiction:
Improvepluripotency generation reliabilityVSAvoidmethod complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent removes the need for exogenous reprogramming factors by extracting only the essential stress conditions (mechanical stimulation and chemical stress with ATP and low pH) that naturally induce pluripotency. This eliminates the complex viral transduction and factor introduction steps while maintaining pluripotency generation capability.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts harmful or controversial elements (exogenous factor introduction, viral transduction) into beneficial natural stress responses. By using controlled mechanical stress and chemical stress (ATP treatment at pH 4.5-6.0), the method harnesses the cell's own stress-response pathways to induce pluripotency without foreign genetic material.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Quantity of substance

If traditional methods are used to obtain pluripotent cells, then embryonic tissue or cord blood can be sourced, but tissue availability is limited

Engineering Contradiction:
Improvepluripotent cell availabilityVSAvoidtissue source versatility
Core Design Contradiction:
Quantity of substanceVSAdaptability or versatility

Solution Approach 1:

The patent makes the method universally applicable to various somatic cell types (fibroblasts, keratinocytes, epithelial cells, etc.) by using general stress conditions rather than cell-type-specific factors. This multi-functional approach allows pluripotency induction across diverse tissue sources, eliminating the limitation of scarce embryonic or cord blood tissues.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The method enables autologous pluripotent cell generation by using the patient's own somatic cells subjected to stress conditions. This self-service approach eliminates the need for donor tissues (embryonic or cord blood) and allows unlimited expansion from a single patient sample, vastly improving cell availability.

Inventive Principle:
Principle #25Self-service

3Ease of manufacture

If mechanical stimulation and chemical stress are applied to somatic cells, then pluripotent cells are generated without exogenous factors, but the stress conditions must be precisely controlled

Engineering Contradiction:
Improvepluripotent cell production simplicityVSAvoidstress condition control precision
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent defines specific parameter ranges for stress conditions (ATP concentration at 1-50 mM, pH 4.5-6.0, treatment duration of at least 1 minute) that balance simplicity with precision. These quantified parameters provide clear manufacturing guidelines while remaining experimentally accessible, resolving the contradiction between ease of production and precision control.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3119877B1Methods relating to pluripotent cells
Publication Date: 2024.10.23 VCELL THERAPEUTICS INC
  • EP3119877B1 patent drawingFigure 1A~1B
  • EP3119877B1 patent drawingFigure 1C~1D
  • EP3119877B1 patent drawingFigure 2A

AI summary

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.